Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. The Bridge Message Board

French Company Develops Promising Injectable Iverm

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 126683
(Total Views: 202)
Posted On: 01/17/2022 10:23:11 AM
Posted By: Rusty
Re: Bhawks #75920
French Company Develops Promising Injectable Ivermectin Treatment, But There’s a Catch
January 14, 2022

Anything that has the Bill Gates stamp of approval is instantly suspicious, and the Bill and Melinda Gates Foundation is behind the company making the Ivermectin injections.

Ivermectin has been shown by numerous studies to be effective against the coronavirus.

The fact that it’s being suppressed by our own government and panned by mainstream media tells me there’s something beneficial about the drug.

They wouldn’t call it a “horse dewormer” unless they believed it was either truly dangerous or so effective that it could derail their universal vaccine objectives.

We know it’s not the former because the government has been recommending Ivermectin for years to people coming to America from Africa.

They can’t say it’s dangerous to some but recommend it to others unless there’s a different agenda at play.

There is good reason to have hope for a new way to deliver IVM to millions of people to fight COVID variants. It offers a very sound alternative to vaccines.

With all of the considerable controversy about using IVM for treating and preventing COVID, something has slipped the attention of its supporters and critics. A relatively small French company has spent the past year or more developing an injectable product of IVM for prophylactic use and have it last in the body for months.

It has successfully completed a safety study for relatively high doses of IVM over long periods. The company tested IVM taken daily in oral form to simulate the continuous release of the active substance by a long-acting injectable. It found the results fully supportive of their injectable approach.

If the company is able to get the commercial product into the market and, if needed, get regulatory approval, their product could compete against COVID vaccines and avoid the need for the new Pfizer and Merck antiviral treatment drugs.

One can imagine that this innovative product could be just like annual flu vaccines in how it is administered to large numbers of people in a multitude of places, including medical offices, drug stores and supermarket pharmacies. And it would be wonderful if medical insurance covered it like it does for flu shots.

Here is some more information about this venture: The company is MedinCell. It has received financial support from the French government. It was started with the help of the Bill and Melinda Gates Foundation.

At its website it is possible to download a March 2021 lengthy and detailed assessment and review of IVM focusing on its history of intense global use and safety. The title is Medical Safety of Ivermectin. Here are the conclusions:

“Hundreds of millions of human subjects have been treated with ivermectin for curative or prophylactic purposes worldwide over the last 3 decades. The reference list of this report demonstrates that a large body of data is available, which allows for a detailed analysis of ivermectin medical safety.

Undoubtedly, uncertainties remain regarding ivermectin pharmacological effects and mechanisms of action, but when removed, this is not anticipated to alter the main conclusions of this report in any significant way as they rely on an extensive and consistent body of medical publications.

Taking into account all the above, the author of the present analysis of the available medical data concludes that the safety profile of ivermectin has so far been excellent in the majority of treated human patients so that ivermectin human toxicity cannot be claimed to be a serious cause for concern.”

https://truthbasedmedia.com/2022/01/14/french...s-a-catch/

Clinical Trial Conducted by MedinCell Confirms the Safety of Continuous Administration of ivermectin

https://www.businesswire.com/news/home/202104...-of-Contin


(1)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us